News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases > Gastroenterology

      Chronic Gastritis Treatment & Management

      Updated: Jun 07, 2019
      • Author: Akiva J Marcus, MD, PhD; Chief Editor: BS Anand, MD  more...
      • Print
      Treatment

      Approach Considerations

      Treatment of chronic gastritis can be aimed at a specific etiologic agent, if such an agent is known. For example, the treatment approach for H pylori infection is described in detail below. (See also American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection.) When gastritis represents gastric involvement of a systemic disease, treatment is directed toward the primary disease.

      Some entities manifested by chronic gastritis do not have well-established treatment protocols. For example, in lymphocytic gastritis, some cases of spontaneous healing have been reported. However, because the disease has a chronic course, treatment is recommended. Some studies have reported successful treatment of exudative lymphocytic gastritis with omeprazole.

      Next:

      Pharmacotherapy for H pylori

      At first, specific recommendations for H pylori eradication were limited to peptic ulcer disease. However, the 1997 Digestive Health Initiative (DHI) International Update Conference on H pylori broadened the recommendations for H pylori testing and treatment. H pylori testing and eradication were also recommended after resection of early gastric cancer and for low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Furthermore, it is now widely accepted that if H pylori is identified as the underlying cause of gastritis, it should be eradicated.

      H pylori infection is not easily cured, and research has shown that multidrug therapy is required. As with any bacterial infection, therapy must include antimicrobial agents to which the bacterium is sensitive. Antibiotics that have proven effective against H pylori include clarithromycin, amoxicillin, metronidazole, tetracycline, and furazolidone. Cure rates with single antibiotics have been poor (0%-35%). Monotherapy is associated with the rapid development of antibiotic resistance, especially to metronidazole and clarithromycin. Probiotic supplementation has shown promising results when included in the treatment regimen. [100, 101]

      Five regimens are approved by the US Food and Drug Administration (FDA) for the treatment of H pylori infection. One is a version of the traditional bismuth-metronidazole-tetracycline (BMT) triple therapy, which is commercially available as Helidac (Prometheus Laboratories, San Diego, CA). The antibiotics and bismuth are provided in a convenient dose pack that is thought to enhance compliance.

      Three different combinations using clarithromycin have been approved, including 2 dual therapies consisting of 500 mg of clarithromycin 3 times daily plus either omeprazole or ranitidine bismuth citrate. The cure rates reported in the packaging literature suggest that the 3 combinations are similarly effective.

      Clinical experience has shown that the most effective of these regimens is BMT triple therapy, followed by ranitidine bismuth citrate plus clarithromycin and then by omeprazole plus clarithromycin.

      Because higher success rates can be achieved when a third drug is added to the dual therapies, most authorities now recommend triple-drug combinations. This recommendation was confirmed by the FDA’s approval of a combination regimen comprising the proton pump inhibitor (PPI) lansoprazole, clarithromycin, and amoxicillin. The cure rate with this combination exceeds 85%. A 2-drug regimen consisting of lansoprazole plus amoxicillin was also approved, but it yields tremendously variable results and thus is a very poor choice.

      In a clinical trial, Rahmani and colleagues evaluated therapy regimens in 100 patients with chronic gastritis who had been infected by H pylori. They found that the combination of triple therapy with coenzyme Q10 (CoQ10) was effective in ameliorating mucosal inflammation and oxidative stress in patients with chronic gastritis. [102]

      The most widely used regimens for eradicating H pylori are triple therapies, which are recommended as first-line treatments; quadruple therapies [103] are recommended as second-line treatment when triple therapies fail. With either type of regimen, the best results are achieved by administering therapy for 10-14 days, though some studies have limited the duration of treatment to 7 days. The accepted definition of cure is that no evidence of H pylori exists for 4 or more weeks after ending the antimicrobial therapy.

      Do not administer antibiotic therapy if the patient does not have a confirmed infection, and be sure to assess the results of the therapy carefully. Manage cases of subsequent H pylori eradication failure on a case-by-case basis, and base antibiotic selection on pretreatment antibiotic sensitivity test results.

      Triple therapies (with indicated adult dosing)

      Twice-daily PPI or ranitidine bismuth citrate triple therapies include the following:

      • Lansoprazole 30 mg, omeprazole 20 mg, or ranitidine bismuth citrate 400 mg orally twice daily

      • Clarithromycin 500 mg orally twice daily

      • Amoxicillin 1000 mg or metronidazole 500 mg orally twice daily

      Pack kits containing triple therapies are available as a combination of lansoprazole, amoxicillin, and clarithromycin (PrevPac; Takeda Pharmaceuticals America, Deerfield, IL) or a combination of bismuth subsalicylate, tetracycline, and metronidazole (ie, Helidac).

      PrevPac contains drug combinations in the dosage recommended as first-line treatment by the Maastricht 2-2000 Consensus Report in Europe. [104] The components are as follows:

      • Lansoprazole 30 mg orally twice daily

      • Clarithromycin 500 mg orally twice daily

      • Amoxicillin 1000 mg orally twice daily

      The components of Helidac triple therapy are as follows:

      • Bismuth subsalicylate 525 mg (2 chewable 262.4-mg tablets) 4 times daily

      • Metronidazole 250 mg 4 times daily

      • Tetracycline hydrochloride 500 mg 4 times daily

      Quadruple therapies (with indicated adult dosing)

      Quadruple therapy for H pylori infection typically includes the following:

      • PPI (lansoprazole 30 mg or omeprazole 20 mg) orally twice daily

      • Tetracycline HCl 500 mg orally 4 times daily

      • Bismuth subsalicylate 120 mg orally 4 times daily

      • Metronidazole 500 mg orally 3 times daily

      Treatment of H pylori infection in children

      Optimal therapy for H pylori infection in childhood is not well established. Treatment has not been studied extensively, and there is no consensus as to the best regimen. However, the benefits of treating the infection in patients with duodenal ulcer are obvious, whereas the benefits of treating children who are asymptomatic remain controversial. Although the literature is replete with contrary recommendations, many authorities now recommend treating all people, adults and children, in whom H pylori infection is demonstrated.

      Isolated studies have shown eradication efficiencies with triple therapies, ranging from 56%-87% of the cases. In children, clarithromycin and metronidazole H pylori resistance is a problem in several countries, resulting in less efficient eradication regimens.

      In a study of triple therapy with lansoprazole 0.75 mg/kg plus amoxicillin 25 mg/kg plus clarithromycin 10 mg/kg given twice daily for 7 days, the eradication rate was 87%. A similar study used the same drugs but different dosages—lansoprazole 0.45 mg/kg/day in 2 doses (maximum dose, 15 mg twice daily), amoxicillin 40 mg/kg/day in 2 doses (maximum dose, 1 g twice daily), and clarithromycin 250 mg (for age < 10 y) or 500 mg (for age >10 y) twice daily for 2 weeks. This protocol eradicated bacteria in only 56% of children.

      Eradication rates in children have been reported to be as high as 96% with alternative eradication regimens that include amoxicillin, bismuth, and metronidazole.

      The adverse effects of the various regimens are similar in children and adults. Bismuth toxicity is not a concern in children receiving H pylori therapy, but salicylate toxicity from the use of bismuth subsalicylate is. Inform parents of the presence of subsalicylate. Ideally, children younger than 16 years should not receive salicylate-containing compounds, because of the risk of Reye syndrome.

      Previous
      Next:

      Long-Term Monitoring

      If a patient was treated for H pylori infection, confirm that the organism has been eradicated. Evaluate eradication at least 4 weeks after the beginning of treatment. Eradication may be assessed by means of noninvasive methods such as the urea breath test or the stool antigen test.

      Follow-up may be individualized, depending on the findings during endoscopy. For example, if dysplasia is found at endoscopy, increased surveillance is necessary. For patients with atrophic gastritis or dysplasia, follow-up endoscopy is recommended after 6 months.

      Previous
      Medication
       
       
      Media Gallery
      of 7
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.